Latest Ratios: P/E Ratio -75.4x · EV/EBITDA N/A · ROE -27.8%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.6B | $2.5B | $3.5B | $2.8B | $4.4B | $15.8B | $31.0B | $14.9B | — | — |
| Enterprise Value | $4.8B | $2.7B | $3.6B | $2.9B | $4.4B | $15.7B | $31.0B | $14.8B | — | — |
| P/E Ratio → | -75.41 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 15.28 | 8.90 | 19.73 | 16.62 | 23.50 | 102.07 | 315.46 | 174.93 | — | — |
| P/B Ratio | 19.19 | 10.95 | 17.44 | 9.18 | 9.38 | 26.08 | 41.76 | 26.06 | — | — |
| P/FCF | — | — | — | — | — | — | — | 76.63 | — | — |
| P/OCF | — | — | — | — | — | — | — | 72.45 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.65 | 19.96 | 16.82 | 23.60 | 101.89 | 315.30 | 174.22 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 76.32 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.2% | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% | 73.8% | 64.7% | 59.2% |
| Operating Margin | -20.6% | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | -155.3% | -92.1% | -89.4% | -115.7% |
| Net Profit Margin | -21.5% | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.6% | -83.4% | -111.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.8% | -27.8% | -62.5% | -58.3% | -37.5% | -30.8% | -22.3% | -43.8% | — | — |
| ROA | -11.3% | -11.3% | -26.6% | -29.7% | -22.5% | -20.3% | -14.4% | -11.0% | -13.4% | -11.8% |
| ROIC | -12.6% | -12.6% | -41.6% | -41.3% | -28.4% | -24.0% | -18.5% | -15.5% | -14.9% | — |
| ROCE | -13.2% | -13.2% | -32.0% | -34.4% | -25.7% | -23.0% | -16.6% | -13.7% | -15.3% | -13.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.25 | 1.25 | 0.44 | 0.32 | 0.23 | 0.18 | 0.15 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.93 | 0.20 | 0.11 | 0.04 | -0.05 | -0.02 | -0.11 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -0.31 | — | — |
| Interest Coverage | -4.05 | -4.05 | -12.78 | -15.33 | -46.28 | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.34 | 3.34 | 2.89 | 4.66 | 5.12 | 3.54 | 6.91 | 7.82 | 7.93 | 9.77 |
| Quick Ratio | 3.23 | 3.23 | 2.81 | 4.50 | 4.99 | 3.37 | 6.78 | 7.71 | 7.58 | 9.54 |
| Cash Ratio | 2.52 | 2.52 | 2.27 | 3.94 | 4.54 | 3.10 | 6.54 | 7.37 | 7.24 | 9.15 |
| Asset Turnover | — | 0.54 | 0.33 | 0.26 | 0.22 | 0.17 | 0.09 | 0.09 | 0.17 | 0.11 |
| Inventory Turnover | 7.27 | 7.27 | 8.54 | 5.23 | 4.01 | 2.56 | 1.60 | 2.46 | 2.51 | 3.27 |
| Days Sales Outstanding | — | 66.37 | 85.11 | 81.39 | 78.90 | 41.17 | 37.27 | 54.39 | 31.52 | 52.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 1.3% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $152M | $147M | $144M | $143M | $140M | $131M | $124M | $105M | $105M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADPT stock.
Adaptive Biotechnologies Corporation's current P/E ratio is -75.4x. This places it at the 50th percentile of its historical range.
Adaptive Biotechnologies Corporation's return on equity (ROE) is -27.8%. The historical average is -40.4%.
Based on historical data, Adaptive Biotechnologies Corporation is trading at a P/E of -75.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Adaptive Biotechnologies Corporation has 74.2% gross margin and -20.6% operating margin.
Key Metrics
Top Statement Risk
Thin liquidity against rising debt
Metrics are mathematically derived from official filings.
Premium Multiples Against Negative Earnings
Based on reported figures, ADPT trades at a trailing P/S of 14.97 and P/B of 18.79 while TTM P/E is negative at -73.85, a combination that prices in revenue durability and a future margin inflection rather than current earnings.
Because the P/E is meaningless with losses, the price-to-sales multiple becomes the operative anchor, and at roughly 15 times trailing sales the market appears to be assigning substantial value to the immune medicine platform and clonoSEQ growth. The P/B of 18.79 against equity of only about $176M suggests the stock is valued far above book, which investors should interpret as a bet on future cash generation rather than asset backing. Multiples of this magnitude warrant further investigation into whether forward revenue assumptions are realistic given the unreconciled profitability claims.
Gross Margin Strength Versus Operating Drag
As reported in quarterly statements, gross margin expanded from 55.3% in 2024Q2 to 76.2% in 2026Q3, yet operating margin of -0.5% in the latest quarter still signals that overhead has only recently approached revenue levels.
The gross margin trajectory is structurally encouraging and consistent with a high-value diagnostic service carrying low variable sequencing cost. However, the operating margin remained deeply negative at -22.0% in 2026Q2 and -20.6% on a trailing basis, which indicates R&D and SG&A still absorb most of the gross profit. The apparent breakeven quarter should be treated cautiously, since the net margin of 3.4% sits well above operating margin, suggesting non-operating items drove the result.
Debt Scaling Faster Than Earnings Capacity
According to recent SEC filings, ADPT's total debt rose from $84.4M in 2025Q2 to roughly $409M in 2026Q3, while interest coverage remains negative at -0.91, indicating operating earnings do not currently cover interest obligations.
Debt/equity of 2.22 in the latest quarter, versus 0.40 to 0.47 through 2025, reflects a sharp shift in capital structure that the income statement has not yet offset. Negative interest coverage means debt service depends on cash reserves or new financing rather than operating earnings. This pattern suggests refinancing and covenant risk should be monitored closely, though the exact terms are not disclosed in the provided data.
Comfortable Current Ratio, Thin Cash Cushion
As reported in financial statements, the current ratio of 3.97 and quick ratio of 3.87 in 2026Q3 look strong, yet cash of about $75.6M is modest relative to recurring operating losses and a rapidly expanded debt load.
The high current ratio is largely supported by receivables and other current assets rather than a deep cash reserve, so headline liquidity may overstate true stress resilience. Under a severe downturn, the cash balance would likely cover only a limited period of burn, suggesting the company could face pressure to raise capital or reduce spending. Investors should weigh the current ratio against the cash runway rather than treat it as evidence of durable solvency.
Misapplied Current Ratio Masks Cash Risk
The current ratio is most commonly misapplied to ADPT because it counts receivables and inventory-like assets as liquidity, which may flatter a company whose ability to meet obligations depends on converting sales into cash.
For a diagnostic business with a DSO of 64 days and a cash conversion cycle of 84 days, receivables are not immediately available to fund operating losses or debt service. A cash ratio or months-of-runway measure, computed against trailing operating cash burn, would better reveal whether the 3.97 current ratio reflects durable liquidity. Using such an adjusted metric would likely show a tighter position than the headline ratio implies.